Allergan Inc (AGN) 196.00 $AGN
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.00 (-1.40), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), NVS: 91.76 (-0.27)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 196.00 (-1.40), HCA: 65.75 (-3.22), BIDU: 236.54 (-0.36), ZBRA: 72.59 (-1.29), SWKS: 59.88 (-2.26), ALK: 55.14 (-0.26), CELG: 106.45 (-0.69)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), AZN: 72.88 (+0.03), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), HHC: 149.47 (-0.85), PAH: 25.79 (+0.11), CP: 206.47 (+0.78), APD: 134.94 (-0.07), BKW: 32.60 (-0.72)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), AUXL: 32.75 (-0.52), SLXP: 91.47 (-47.08)
Cramer: Salix Pharmaceuticals' Audit Committee Review Is Concerning
at The Street - Fri Nov 07, 9:54AM CST
TheStreet's Jim Cramer takes a look at Salix Pharmaceuticals, whose stock is plunging after the company announced a slew of bad news.
AGN: 196.00 (-1.40), SLXP: 91.47 (-47.08)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), SRDX: 20.44 (-0.56), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21)
Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan
Thomson Reuters ONE - Fri Nov 07, 2:20AM CST
Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan . Ad hoc announcement according to 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AGN: 196.00 (-1.40)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 196.00 (-1.40), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21), HSP: 56.32 (-0.32)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), MSFT: 48.68 (-0.02), VZ: 50.86 (+0.58)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), PRGO: 155.77 (+3.28), ABBV: 61.50 (-1.21)
Uptrend Call Working As Allergan Stock Rises 18.8% (AGN)
Comtex SmarTrend(R) - Thu Nov 06, 9:59AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 18.85% as of today's recent price of $198.60.
AGN: 196.00 (-1.40)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 196.00 (-1.40), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), ABBV: 61.50 (-1.21)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), SWKS: 59.88 (-2.26), AKRX: 36.59 (-1.29), SLXP: 91.47 (-47.08), AAPL: 109.01 (+0.31)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47)
New Survey Shows Nearly 60% Of Women Say They Would Rather Have A More Youthful Looking Face Than A More Youthful Looking Body(1)
PR Newswire - Wed Nov 05, 3:25PM CST
According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
AGN: 196.00 (-1.40)
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 196.00 (-1.40)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.00 (-1.40), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), NVS: 91.76 (-0.27)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 196.00 (-1.40), HCA: 65.75 (-3.22), BIDU: 236.54 (-0.36), ZBRA: 72.59 (-1.29), SWKS: 59.88 (-2.26), ALK: 55.14 (-0.26), CELG: 106.45 (-0.69)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), AZN: 72.88 (+0.03), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), HHC: 149.47 (-0.85), PAH: 25.79 (+0.11), CP: 206.47 (+0.78), APD: 134.94 (-0.07), BKW: 32.60 (-0.72)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), AUXL: 32.75 (-0.52), SLXP: 91.47 (-47.08)
Cramer: Salix Pharmaceuticals' Audit Committee Review Is Concerning
at The Street - Fri Nov 07, 9:54AM CST
TheStreet's Jim Cramer takes a look at Salix Pharmaceuticals, whose stock is plunging after the company announced a slew of bad news.
AGN: 196.00 (-1.40), SLXP: 91.47 (-47.08)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), SRDX: 20.44 (-0.56), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21)
Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan
Thomson Reuters ONE - Fri Nov 07, 2:20AM CST
Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan . Ad hoc announcement according to 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AGN: 196.00 (-1.40)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 196.00 (-1.40), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21), HSP: 56.32 (-0.32)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), MSFT: 48.68 (-0.02), VZ: 50.86 (+0.58)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), PRGO: 155.77 (+3.28), ABBV: 61.50 (-1.21)
Uptrend Call Working As Allergan Stock Rises 18.8% (AGN)
Comtex SmarTrend(R) - Thu Nov 06, 9:59AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 18.85% as of today's recent price of $198.60.
AGN: 196.00 (-1.40)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 196.00 (-1.40), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), ABBV: 61.50 (-1.21)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), SWKS: 59.88 (-2.26), AKRX: 36.59 (-1.29), SLXP: 91.47 (-47.08), AAPL: 109.01 (+0.31)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47)
New Survey Shows Nearly 60% Of Women Say They Would Rather Have A More Youthful Looking Face Than A More Youthful Looking Body(1)
PR Newswire - Wed Nov 05, 3:25PM CST
According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
AGN: 196.00 (-1.40)
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 196.00 (-1.40)
